Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
about
In vitro comparative models for canine and human breast cancersBiomarkers in triple negative breast cancer: A reviewMultiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancerBreast cancer chemoprevention: old and new approachesPotential use of COX-2-aromatase inhibitor combinations in breast cancerInhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expressionIL-1 does not reverse the anti-proliferative effect of aspirin in breast cancer cellsInflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancerGemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkersCoexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer.COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situEvaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial dataFunctional promoter -765 G > C variant in COX-2 gene is associated with the susceptibility of breast cancer in Chinese Han women.COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer.Functional interaction between acyl-CoA synthetase 4, lipooxygenases and cyclooxygenase-2 in the aggressive phenotype of breast cancer cells.Expression and prognostic significance of Cox-2 and p-53 in Hodgkin lymphomas: a retrospective study.COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatmentSuppression of integrin alpha3beta1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells.Association of the three common SNPs of cyclooxygenase-2 gene (rs20417, rs689466, and rs5275) with the susceptibility of breast cancer: an updated meta-analysis involving 34,590 subjects.The functional interaction between Acyl-CoA synthetase 4, 5-lipooxygenase and cyclooxygenase-2 controls tumor growth: a novel therapeutic target.Genetic variants in COX-2, non-steroidal anti-inflammatory drugs, and breast cancer risk: the Western New York Exposures and Breast Cancer (WEB) Study.Celecoxib and GABA cooperatively prevent the progression of pancreatic cancer in vitro and in xenograft models of stress-free and stress-exposed miceTumor-secreted PGE2 inhibits CCL5 production in activated macrophages through cAMP/PKA signaling pathway.Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo.Urinary prostaglandin E2 metabolite and breast cancer risk.Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro.Cystic duct dilatations and proliferative epithelial lesions in mouse mammary glands upon keratin 5 promoter-driven overexpression of cyclooxygenase-2.Detection of non-melanoma skin cancer by in vivo fluorescence imaging with fluorocoxib A.Opposing roles for mammary epithelial-specific PPARγ signaling and activation during breast tumour progressionA novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cellsCyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switchOverexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neuPhase ii trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer.Cyclooxygenase-2 knockdown using retinoic acid chalcone (RAC), a promising therapeutic strategy for colon cancerInteraction between cyclooxygenase-2 and insulin-like growth factor in breast cancer: A new field for prevention and treatmentSemi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays.Comparison of increased aromatase versus ERα in the generation of mammary hyperplasia and cancer.Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinaseCOX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ.Resveratrol Treatment Inhibits Proliferation of and Induces Apoptosis in Human Colon Cancer Cells.
P2860
Q26752714-71311F83-99FE-4FBA-A2C4-EC13C1CB515FQ26775094-9179F1B5-C5E1-421C-8EFF-AAB7B1EB2F25Q26828414-5E25BF39-22D5-40B5-9127-C32E53B5869EQ27693259-30B4AA98-D490-43CA-8A5F-502530E9F56CQ28187414-02881E4E-2D6B-40A8-85BE-5452C088CEDEQ28199319-3E09C37C-0087-4997-BC60-DEC5A601067BQ28200420-BB91BBB7-08FA-4D79-8E16-269A43ADC820Q28218639-D2A057E5-F7E2-4974-A036-2D0634F157C3Q28471821-2DA8A325-0B67-4E8A-9BBF-0A266AF47C54Q33314445-AE00DB5D-BA2F-4987-8676-571D029E1D0DQ33317621-0D168926-3B90-4D16-865D-7B75616182A0Q33388617-3B3E1221-8358-4CE4-B4C0-FF2F929AD224Q33600759-DA5C719F-CD2D-43DB-A770-60636FB0FCD1Q33747000-87C737DA-E7A7-4F03-AF77-346DFCCF8012Q33750005-BD4A0AB3-34E1-49BB-AEC0-75340B201FF7Q33784787-6A72E600-5D3E-44F6-BA5B-2412E75B2228Q33877411-3CF913D0-F26C-4C1B-A4B1-52CA4AC27028Q34032403-DCE05363-156A-4A97-85C8-CB9B6B3CF009Q34119332-972AB68D-3A25-4C40-B733-AF3D4476ED8BQ34342416-6C60224D-673A-4422-B7A8-8C7842FADEFEQ34351250-2A94CB32-C878-402C-A4F5-904D35AF5421Q34391552-53C6EC56-E0CD-4C1A-836C-A2F358671BF0Q34503208-637B75CA-DC89-46A1-9713-8EBAFD29D115Q34578154-7D361D1F-3FD4-4E5B-A424-41B6474CCE0BQ34641787-64C16D3A-554B-4D1C-AE20-2439E2C9A5A3Q34908885-D27CB769-6005-467D-91E1-651C4B6DAF8CQ35083639-49BBCC65-1132-4DF6-81BE-66FDEEDC6B5CQ35152553-0030FDC9-BFFA-4FAE-999A-1C3F1EF4BE0AQ35576310-5FBEE2B9-0F61-4D5D-84DE-C4E2EFE5EC76Q35633657-CE8AA9A6-DAAC-4A3D-AA3A-1C4EC6E883D8Q35732971-4B82FEEC-63C2-46D6-8154-E04BBBE5A14BQ35770111-D8EA97E7-28E9-4589-B256-C5B4DEDFC671Q35872701-6CFEA9CE-9EBC-482F-8DC9-C44E36365351Q35929848-3615DD9A-50AD-4AF2-906B-23A8951D1F56Q35995604-0AC97699-5D6A-4D62-A0F5-18940DB7696DQ36026180-1858ECFC-B728-45CD-812B-27C01AED5D73Q36119454-6E10B40A-132C-4C7E-A048-3D2E3E125292Q36135818-40FD6CC1-7149-4DD5-8C9A-C3C98537B68DQ36694470-A1C165F9-9C7D-4206-B1A0-A12590A7ADB9Q36771532-42B2B364-25C7-4401-A547-9A1A9674E6E2
P2860
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Cyclooxygenase-2 expression in ...... cent ductal carcinoma in situ.
@en
type
label
Cyclooxygenase-2 expression in ...... cent ductal carcinoma in situ.
@en
prefLabel
Cyclooxygenase-2 expression in ...... cent ductal carcinoma in situ.
@en
P2093
P1433
P1476
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ
@en
P2093
Aysegul Sahin
Elizabeth Half
Frank A Sinicrope
Karin Gwyn
Kyle Wathen
Xi Ming Tang
P304
P407
P577
2002-03-01T00:00:00Z